HC Wainwright keeps LENZ Therapeutics at Buy, cuts price target to $16
HC Wainwright maintained its Buy rating on LENZ Therapeutics and cut the price target to $16 from $38, according to TradingView citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
HC Wainwright & Co. kept its Buy rating on LENZ Therapeutics but reduced the price target from $38 to $16, a 57.9% cut. TradingView reported the change, citing data from Benzinga.
The new target implies a 358.5% upside from the October 29 close of $3.49. More price target data and analyst ratings for the company are available on TradingView.
why it matters
A single broker's target revision rarely moves the broader market, but for LENZ shareholders it signals a sharp reassessment of the company's valuation by this analyst.
tags
instruments
sources
- HC Wainwright & Co. maintains LENZ Therapeutics at Buy, lowers price target to $16 from $38 — TradingView, 30 October 2026 at 11:38 UTC
- LENZ Therapeutics Is Maintained at Buy by HC Wainwright & Co. — Dow Jones Newswires, 30 October 2026 at 11:50 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗